This Week Could Make or Break Valeant Pharmaceuticals Intl Inc.

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) will host its investor day on Wednesday. The stakes couldn’t be higher.

| More on:
The Motley Fool

It seems that every week, the pressure only grows on Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). Lawmakers are outraged over the company’s steep drug price increases, regulators are scrutinizing its patient-assistance programs, and questions remain about Valeant’s use of specialty pharmacies.

Valeant has not been standing still as these problems mount. The company has been outspoken in defending its business model and has engaged in a public-relations battle with its critics. It cut ties with the controversial specialty pharmacy Philidor. And most recently, Reuters has reported that Valeant has hired a prominent Washington DC attorney along with “crisis public-relations experts with political sources.”

This week will be especially important for Valeant as the company prepares for its investor day on Wednesday.

Looking for answers

Valeant and its allies (mainly Bill Ackman) have maintained that the company has been transparent throughout this process. But there are still some big questions that need to be addressed.

First of all, what exactly was Valeant’s role in Philidor’s operations? Valeant maintains that Philidor operated independently, but others–including The Wall Street Journal–disagree. Valeant is currently conducting an investigation into the matter, and investors will be expecting some insight about it on Wednesday.

More importantly, to what extent is Valeant’s business model under threat? The company has done very well in recent years by making acquisitions and steeply hiking prices. But with all of this scrutiny, further price hikes are essentially off the table. Acquisitions will also take a back seat due to Valeant’s falling share price and its high debt levels.

The big picture

There are still many analysts who think you should buy Valeant. For example, JP Morgan analyst Chris Schott notes how the company is trading at just six times his estimate for 2016 earnings.

But let’s not forget what these earnings estimates are based on. Valeant makes its money primarily from charging very high prices for drugs that often have generic alternatives. Now with all this scrutiny, Valeant will find itself under attack from insurers and pharmacy benefit managers, and drug prices may have to be dramatically lowered in response. Making matters worse, without the ability to make more acquisitions, Valeant won’t be able to grow its way out of this mess.

So if you’re thinking of buying Valeant shares, just remember that there are some extreme risks you need to watch out for. Hopefully, the company will clear some of these up on Wednesday.

In any case, there will certainly be a lot of people watching, and this will be a pivotal week for the company.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned.

More on Investing

Happy shoppers look at a cellphone.
Stocks for Beginners

Why Is Aritzia Stock Up 22% After Earnings?

Aritzia stock (TSX:ATZ) surged in share price after its last earnings, so is it still a good buy? Or should…

Read more »

Growth from coins
Dividend Stocks

1 Dividend-Growth Stock to Buy and Hold for the Next 15 Years

CN Rail (TSX:CNR) is a dividend-growth giant worth buying on weakness in July.

Read more »

analyze data
Dividend Stocks

The 5.11% Dividend Stock Set to Dominate the TSX

Brookfield Infrastructure (TSX:BIP.UN) has already been dominating the TSX, but more is certainly on the way.

Read more »

stock analysis
Investing

3 TSX Stocks You Can Confidently Buy Now and Hold Forever

These three companies are some of the top stocks on the TSX, giving you the confidence to buy now and…

Read more »

sale discount best price
Dividend Stocks

3 Remarkably Cheap TSX Stocks to Buy Right Now

Investing in undervalued TSX stocks such as Eldorado Gold should help Canadians derive steady gains in 2024 and beyond.

Read more »

Piggy bank with word TFSA for tax-free savings accounts.
Retirement

2 Magnificent Dividend Stocks I Plan to Add to My TFSA in August

Here are two magnificent dividend stocks long-term investors may certainly want to hone in on before the next bull cycle…

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Dividend Stocks

1 TSX Stock That Could Help Set You Up for Life

Early investors in Intact Financial (TSX:IFC) stock could earn a 17% dividend yield in 2024. Here's how IFC stock could…

Read more »

Canadian Dollars
Dividend Stocks

2 Magnificent Ultra-High-Yield Dividend Stocks That Are Screaming Buys in July

These two top Canadian dividend stocks offer over 8% annualized dividend yield in July, making them really attractive to buy…

Read more »